Trump Lights Up Cannabis Sector With CBD for Seniors
Trump’s surprising nod to CBD sparks record gains for a long-struggling cannabis sector
Wall Street woke up to a jolt when U.S. President Donald Trump took to Truth Social and proclaimed that cannabidiol could transform senior healthcare. Markets rarely ignore presidential endorsements, especially when tied to an industry long stifled by regulation. Shares of cannabis companies erupted in premarket trading, sending Tilray Brands up more than 30 percent, Canopy Growth and Aurora Cannabis sharply higher, and Cronos Group not far behind. The AdvisorShares Pure U.S. Cannabis ETF surged more than 25 percent, putting it on track for a record quarterly gain. For an industry that has seen wild swings over the years, Trump’s message delivered fresh momentum.
The Promise of CBD in Senior Care
Trump’s comments did not come out of thin air. He argued that hemp-derived cannabidiol could help reduce disease progression and serve as an alternative to traditional prescription drugs. For seniors facing chronic conditions, from arthritis to neurological disorders, CBD represents a non-intoxicating option with growing medical interest. His declaration that CBD could “revolutionize senior healthcare” gave investors a powerful narrative. It positioned cannabis not just as a recreational substance but as a potential medical solution, particularly for the country’s fastest-growing demographic.
Behind the rally lies a deeper story of regulatory evolution. Marijuana remains a Schedule I substance under the Controlled Substances Act, alongside heroin, deemed to have high abuse potential and no accepted medical use. But the winds are shifting. The Biden administration previously asked the Department of Health and Human Services to review cannabis, leading to a recommendation to move it to Schedule III, a category that recognizes medical use and carries lighter restrictions. Trump hinted last month that his administration would pursue reclassification as well. While not outright legalization, this step could ease the punishing tax burdens under Section 280E, which prevent cannabis companies from taking standard business deductions. If that barrier falls, the floodgates for institutional investment and stock exchange listings could finally open.
The Market Reaction
Investors responded instantly to the political boost. Tilray, already a volatile favorite among traders, became the star of the morning. Canopy Growth, battered by years of underperformance, also saw a sharp rebound. Aurora Cannabis and Cronos Group joined the rally. Analysts noted that the broader cannabis ETF, MSOS, captured the sector’s newfound energy, reflecting both relief and speculation. Traders understand that cannabis stocks live and die on political signals, and Trump’s comments reignited hopes of structural reform.
Nearly 40 states allow some form of legal cannabis use, whether medical or recreational. Yet at the federal level, prohibition persists. This mismatch has long created headaches for businesses, from banking access to taxation. Reclassification would not erase the divide overnight, but it would represent a powerful first step in narrowing the gap. For companies desperate to expand into mainstream finance and shed their stigma, this could be the break they have been waiting for.
The Road Ahead
For all the euphoria, investors know cannabis remains a volatile bet. Canopy Growth, despite Monday’s bounce, has lost half its value this year. Others have shown resilience, with Cronos and SNDL gaining ground. The sector has seen countless rallies tied to political promises, only to slump when legislation stalls. The question now is whether Trump’s endorsement turns into concrete policy. If reclassification moves forward, Wall Street may treat this industry differently, no longer as a speculative niche but as a legitimate healthcare and consumer sector.
Trump’s embrace of cannabidiol as a tool for senior healthcare lit a fire under cannabis stocks, delivering one of the sector’s strongest rallies in years. Beyond the headlines, the endorsement reflects a broader shift in how America views cannabis, from taboo substance to potential medical ally. The market is betting that political talk will translate into regulatory change. If it does, this could mark the start of a new era for the cannabis industry—one where investors no longer trade on hope alone, but on fundamentals reshaped by law and policy.